MET
2 EU-approved indications of 2 drugs need a MET result, in 1 tumour type, most of them in non-small cell lung cancer.
Approved indications2
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Non-small cell lung cancer2 | ||||
Tabrecta | Alterations leading to METex14 skipping | Monotherapy | 2L advanced | After prior treatment with immunotherapy and/or platinum-based chemotherapy |
Tepmetko | Leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping | Monotherapy | 2L advanced | After prior treatment with immunotherapy and/or platinum-based chemotherapy |
MET by tumour
Label wording2
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Tepotinib (Tepmetko)
TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
- Capmatinib (Tabrecta)
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.